Strategic appointment to support biopharma expansion

Coriolis Pharma has appointed industry heavyweight Peter Sölkner to its Board of Directors, a move that signals the company’s intent to accelerate its global growth strategy and deepen its role as a key partner in biopharma innovation.

Sölkner, who brings over three decades of experience in pharmaceutical services, is best known for his leadership at Vetter Pharma, where he helped scale the business fivefold. Now, as a non-executive director at Coriolis, he’ll lend his expertise to one of the sector’s most respected formulation specialists.

“I’m excited to support Coriolis as it grows its impact in developing life-changing therapies,” said Sölkner. “The team’s scientific excellence and forward-looking approach make it a standout partner in the biotech field.”

Known for its cutting-edge work in biologics, cell and gene therapies, and vaccine development, Coriolis Pharma has earned a reputation as a premier CRDO. The appointment of Sölkner strengthens its Board at a pivotal time, as the company sharpens its focus on integrated services from preclinical through to commercialisation.

Dr Michael Wiggenhorn, Coriolis Founder and Board Member, welcomed the appointment: “Peter’s track record in scaling businesses and his understanding of the CDMO landscape bring exactly the kind of insight we value.”

CEO Silvia Steyrer-Gruber added: “We see our role as a bridge between early discovery and final product. Peter’s experience will help us better support both pharma innovators and manufacturing partners.”

Sölkner’s previous roles at Sartorius and Vetter, combined with his international leadership experience and technical background, make him a strategic asset as Coriolis strengthens its collaborations across the pharmaceutical value chain.

More information online